NCT03367598已完成不适用
Longitudinal Interaction Between APOA5 -1131T>C and Overweight
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 503
- 主要终点
- Brachial-ankle PWV (baPWV)
研究概览
简要总结
The aim of this study is to evaluate whether the longitudinal interaction between APOA5 -1131C variants and overweight could accelerate age-related increases in arterial stiffness and circulating triglycerides in healthy subjects.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Control
- 时间视角
- Prospective
入排标准
- 年龄范围
- 30 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Nondiabetic (fasting serum glucose concentration < 126 mg/dL)
- •Nonobese (BMI ≥ 25 kg/m2)
排除标准
- •Current and/or past history of cardiovascular disease
- •Diabetes mellitus (fasting glucose levels ≥126 mg/dL)
- •Abnormal liver or renal function
- •Thyroid or pituitary disease
- •Pregnancy or lactation
- •Regular use of any medication
结局指标
主要结局
Brachial-ankle PWV (baPWV)
时间窗: 3-year follow-up
cm/s
次要结局
- Triglyceride(3-year follow-up)
研究者
相似试验
已完成
不适用
An observational study on interaction between 5ASA and thiopurine in ulcerative colitisJPRN-UMIN000032775Kitasato University Kitasato Institute Hospital.50
已完成
不适用
Evaluation of the Potential Association Between 5α-reductase Inhibitors Prescription and Occurrence of High Grade Prostate CancersBenign Prostate HyperplasiaNCT02873117Rennes University Hospital5,154
进行中（未招募）
不适用
Comparison of the Effects Noted in The ApoB/ApoA-I ratio Using Rosuvastatin and atorvastatin in patients with acUte coronary Syndrome. - CENTAURUSEUCTR2005-002892-34-IEAstraZeneca SAS1,150
进行中（未招募）
不适用
Comparison of the Effects Noted in The ApoB/ApoA-I ratio Using Rosuvastatin and atorvastatin in patients with acUte coronary Syndrome. - CENTAURUSMen or women who are =18 years old diagnosed with non ST elevation - acute coronary syndrome (NSTE-ACS) and onset of clinical symptoms less than 48 hours at the admission for which a PCI is planned or anticipated. Patients with STEMI and primary PCI planned within 24 hours of admission will not be included. Patients will not be allowed to have taken any cholesterol-lowering medications during 1 month prior to enrolment.EUCTR2005-002892-34-GRAstraZeneca SAS1,150
进行中（未招募）
不适用
Comparison of the Effects Noted in The ApoB/ApoA-I ratio Using Rosuvastatin and atorvastatin in patients with acUte coronary Syndrome. - CENTAURUSMen or women who are >18 and <75 years old diagnosed with non ST elevation - acute coronary syndrome (NSTE-ACS) and onset of clinical symptoms less than 24 hours at the admission for which a PCI is planned or anticipated. Patients with STEMI and primary PCI planned within 24 hours of admission will not be included. Patients will not be allowed to have taken any cholesterol-lowering medications during 1 month prior to enrolment.EUCTR2005-002892-34-PTAstraZeneca SAS1,150